Sandoz International GmbH engages in the development, production, marketing, and distribution of generic medicines, pharmaceutical and biotechnological active substances, and anti-infectives in Germany and internationally. It offers products for various therapeutic areas, including cardiovascular system, central nervous system, gastrointestinal system, muscle and skeletal system, hormone therapy, and respiratory system. The company’s product portfolio ranges from various application forms, such as oral solids through technologies, including inhalers or injectables to transdermal patches, implants, and biopharmaceutical follow-ons. It sells its products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz International GmbH was founded in 1886 and is headquartered in Holzkirchen, Germany. The company has research and development, and production sites in Boucherville, Canada; Buenos Aires, Argentina; Cambe and Taboao da Serra, Brazil; Holzkirchen/Rudolstadt and Barleben, Germany; Kolshet, Kalwe, and Mahad, India; Kundl and Schaftenau, Austria; Menges and Ljubljana, Slovenia; Wilson, North Carolina; Broomfield, Colorado; Gebze and Syntex, Turkey; and Strykow, Poland. Sandoz International GmbH operates as a subsidiary of Novartis AG.

Nabi Biopharmaceuticals company was founded in 1967 and is headquartered in Rockville, Maryland. Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Oxford Gene Technology Ltd. owned company was founded in 1995 by Professor Sir Edwin Southern. Oxford Gene Technology (OGT) provides microarray products and services that enable clinical research and molecular diagnostics in academic, hospital, and government research laboratories. One of its key business areas, licensing, gives companies access to its intellectual property that covers microarrays, genomics, and electrochemistry. OGT's research focuses on developing novel microarray technologies for new applications such as drug discovery and disease diagnosis.

Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimer's disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases.

Mirari Biosciences was founded in 2000 by CEO Mark Martin, who developed the MASC and Peplica technologies. Mirari Biosciences it working to cut down on the time its takes to test new drugs. The first of the company's two primary technologies is microwave-accelerated surface chemistry (MASC) which can speed up drug discovery tests, medical and veterinary diagnostics, and food and water testing by exposing test materials to low-heat microwaves. Its protein amplification technology (Peplica) replicates proteins which helps researchers locate and identify minute levels of proteins.

Schiff Nutrition International, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah. Schiff Nutrition International, Inc. develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. The Company offers a range of capsules, tablets and nutrition bars. Its portfolio of brands includes Schiff, Move Free, MegaRed and Tiger’s Milk, which is marketed through the mass market, including club and health food store distribution channels. The Company markets a range of specialty supplements, vitamins and minerals under the Schiff brand. The Schiff brand specialty supplements are designed to provide consumers with targeted support for their wellness efforts. Its specialty supplements include joint care products marketed under the Schiff brand, including its Move Free and Glucosamine products. Its Move Free product is one of the joint care products in the mass market channel.

Clinical Data, Inc. company was founded in 1969 and is headquartered in Newton, Massachusetts. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers.

Asterand operates a biorepository, but cast out of your mind any visions of pickled livers and brains floating in large clear jars. Asterand, Inc. collects donated specimens of diseased tissue and sells them to researchers to help them better understand and treat such ailments as prostate, breast, and lung cancer, as well as autoimmune, cardiovascular, inflammatory, psychiatric, and respiratory conditions. In addition to supplying these biological samples to researchers, Asterand offers such services as high-throughput screening to speed drug discovery and collaborative research. Asterand, Inc. acquired Pharmagene in a reverse merger.

3SBio Inc. was founded in 1993 and is based in Shenyang, the Peoples Republic of China. 3SBio Inc. is an integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The Company’s recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO, and its legacy products are Intefen and Inleusin. EPIAO is an injectable recombinant human erythropoietin (EPO) that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. 3SBio Inc. had launched TPIAO, its internally developed protein-based therapeutic product. In addition to EPIAO and TPIAO, the Company markets two other protein-based therapeutics.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.